Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2022 08:00 ET | Source: PepGen, Inc.

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

- Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company - - This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary...
April 05, 2022 08:00 ET | Source: PepGen, Inc.

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular...
March 30, 2022 08:00 ET | Source: PepGen, Inc.

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic...
March 15, 2022 08:00 ET | Source: PepGen, Inc.

PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- PepGen Inc., a company advancing the next generation of oligonucleotide therapies for neuromuscular and neurologic diseases, today announced approval by...
January 19, 2022 08:00 ET | Source: PepGen, Inc.

PepGen Appoints Laurie Keating as Chair of Board of Directors

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed...
December 07, 2021 08:00 ET | Source: PepGen, Inc.

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations

Dr. Bracegirdle to lead expanded PepGen Strategy and Operations teamIsami J. Salcedo, experienced biotechnology operations and program management professional, joins as Vice President of Program...
November 08, 2021 08:00 ET | Source: PepGen, Inc.

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya...
October 28, 2021 08:00 ET | Source: PepGen, Inc.

PepGen Appoints Noel Donnelly as Chief Financial Officer

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed...
October 13, 2021 08:00 ET | Source: PepGen, Inc.

PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board

BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of...
September 20, 2021 07:00 ET | Source: PepGen, Inc.

PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James...